Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,.
The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients The Company will host an investor event the same day concurrently with.
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report)’s share price dropped 6% during trading on Monday . The company traded as low as $7.25 and last traded at $7.25. Approximately 249,563 shares changed hands during trading, a decline of 80% from the average daily volume of 1,219,567 shares. The stock had previously closed at $7.71. […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) shares were down 6% during trading on Monday . The company traded as low as $7.25 and last traded at $7.25. Approximately 249,563 shares were traded during trading, a decline of 80% from the average daily volume of 1,219,567 shares. The stock had previously closed at $7.71. […]